Explore the vast range of titles available.

For X1,X2 independently and normally distributed with means θ1 and θ2, variances σ12 and σ22, we consider Bayesian inference about θ1 with the difference θ1-θ2 being lower-bounded by an uncertain m. We obtain a class of minimax Bayes estimators of θ1, based on a posterior distribution for (θ1,θ2)⊤ taking values on R2, which dominate the unrestricted MLE under squared error loss for θ1-θ2≥0. We also construct and study an ad hoc credible set for θ1 with approximate credibility 1-α and provide numerical evidence of its frequentist coverage probability closely matching the nominal credibility level. A spending function is incorporated which further increases the coverage.

2D visual servoing consists in using data provided by a vision sensor for controlling the motions of a dynamic system. Most of visual servoing approaches has relied on the geometric features that have to be tracked and matched in the image acquired by the camera. Recent works have highlighted the interest of taking into account the photometric information of the entire image. This approach was tackled with images of perspective cameras. We propose, in this paper, to extend this technique to central cameras. This generalization allows to apply this kind of method to catadioptric cameras and wide field of view cameras. Several experiments have been successfully done with a fisheye camera in order to control a 6 degrees of freedom robot and with a catadioptric camera for a mobile robot navigation task.

Wastewater treatment for indirect potable reuse (IPR) is a possible approach to address water scarcity. In this study, a novel membrane bioreactor–membrane distillation (MBR-MD) system was evaluated to determine the environmental impacts of treatment compared to an existing IPR facility (“Baseline”). Physical and empirical models were used to obtain operational data for both systems and inform a life cycle inventory. Life cycle assessment (LCA) was used to compare the environmental impacts of each system. Results showed an average 53.7% reduction in environmental impacts for the MBR-MD system when waste heat is used to operate MD; however, without waste heat, the environmental impacts of MBR-MD are significantly higher, with average impacts ranging from 218% to 1400% greater than the Baseline, depending on the proportion of waste heat used. The results of this study demonstrate the effectiveness of the novel MBR-MD system for IPR and the reduced environmental impacts when waste heat is available to power MD.

The BODE score (incorporating body mass index, airflow obstruction, dyspnea and exercise capacity) is used for the timing of listing for lung transplantation (LTx) in COPD, based on survival data from the original BODE cohort. This has limitations, because the original BODE cohort differs from COPD patients who are candidates for LTx and the BODE does not include parameters that may influence survival. Our goal was to assess whether parameters such as age, smoking status and diffusion indices significantly influence survival in the absence of LTx, independently of the BODE. In the present cohort study, the BODE was prospectively assessed in COPD patients followed in a tertiary care hospital with an LTx program. The files of 469 consecutive patients were reviewed for parameters of interest (age, gender, smoking status and diffusing capacity of the lungs for carbon monoxide [DL,CO]) at the time of BODE assessment, as well as for survival status. Their influence on survival independent of the BODE score was assessed, as well as their ability to predict survival in patients aged less than 65 years. A Cox regression model showed that the BODE score, age and DL,CO were independently related to survival ( -values <0.001), as opposed to smoking status. Survival was better in patients aged less than 65 in the first ( =0.004), third ( =0.002) and fourth BODE quartiles ( =0.008). The difference did not reach significance in the second quartile ( =0.13). Median survival for patients aged less than 65 in the fourth BODE quartile was 55 months. According to a receiver operating characteristic curve analysis, the BODE score as well as FEV and DL,CO fared similarly in predicting survival status at 5 years in patients aged less than 65 years. Age and DL,CO add to the BODE score to predict survival in COPD. Assessing survival using tools tested in cohorts of patients younger than 65 years is warranted for improving the listing of patients for LTx.

Evidence and guidelines are becoming increasingly clear about imbalance between the risks and benefits of inhaled corticosteroids (ICSs) in patients with COPD. While selected patients may benefit from ICS-containing regimens, ICSs are often inappropriately prescribed with - according to Belgian market research data - up to 70% of patients in current practice receiving ICSs, usually as a fixed combination with a long-acting β -adrenoreceptor agonist. Studies and recommendations support withdrawal of ICSs in a large group of patients with COPD. However, historical habits appear difficult to change even in the light of recent scientific evidence. We have built a collaborative educational platform with chest physicians and primary care physicians to increase awareness and provide guidance and support in this matter.

Chronic obstructive pulmonary disease (COPD) represents a major health and economic challenge in Belgium, affecting approximately 800,000 individuals, half of whom remain undiagnosed. Beyond respiratory morbidity, COPD patients face substantial cardiopulmonary (CP) risk-encompassing severe exacerbations and cardiovascular (CV) events-that is often under-recognized and insufficiently addressed due to limited clinical awareness, fragmented care, and the absence of national guidance. A multidisciplinary Belgian taskforce (general practitioners, pulmonologists, cardiologists, pharmacists, epidemiologists) convened through structured workshops and iterative consensus-building to develop a pragmatic, evidence-informed care pathway. The recommendations focus on COPD patients with at least one moderate or severe exacerbation, who are at heightened CP risk. This consensus introduces an integrated, stepwise framework that positions CP risk as a central component of COPD management after exacerbation and operationalizes it across primary care, hospitalization, and post-exacerbation follow-up. Core elements include systematic and proactive CP risk identification in primary care, standardized diagnostic workups during hospitalization, and multidisciplinary discharge planning. Pharmacological strategies combine eosinophil-guided inhaler therapy with guideline-directed CV treatment, while non-pharmacological measures reinforce smoking cessation, vaccination, physical activity, and pulmonary rehabilitation. Clear referral thresholds between primary care, pulmonology, and cardiology are defined, supported by patient education and digital monitoring tools. This Belgian consensus complements international guidelines by consolidating fragmented recommendations into coherent, actionable algorithms that bridge gaps in routine practice. Its contribution lies in translating emerging evidence into structured, real-world pathways that integrate respiratory and cardiac care. Adoption of this framework may help reduce exacerbations, improve CV outcomes, and support multidisciplinary COPD care in Belgium.

Patients with chronic airway disease may present features of both asthma and COPD, commonly referred to as asthma-COPD overlap syndrome (ACOS). Recommendations on their diagnosis are diffuse and inconsistent. This survey aimed to identify consensus on criteria for diagnosing ACOS. A Belgian expert panel developed a survey on ACOS diagnosis, which was completed by 87 pulmonologists. Answers chosen by ≥70% of survey respondents were considered as useful criteria for ACOS diagnosis. The two most frequently selected answers were considered as major criteria, others as minor criteria. The expert panel proposed a minimal requirement of two major criteria and one minor criterion for ACOS diagnosis. Respondents were also asked which criteria are important for considering inhaled corticosteroids prescription in a COPD patient. To diagnose ACOS in COPD patients, major criteria were \"high degree of variability in airway obstruction over time (change in forced expiratory volume in 1 second ≥400 mL)\" and \"high degree of response to bronchodilators (>200 mL and ≥12% predicted above baseline)\". Minor criteria were \"personal/family history of atopy and/or IgE sensitivity to ≥1 airborne allergen\", \"elevated blood/sputum eosinophil levels and/or increased fractional exhaled nitric oxide\", \"diagnosis of asthma <40 years of age\"; \"symptom variability\", and \"age (in favor of asthma)\". To diagnose ACOS in asthma patients, major criteria were \"persistence of airflow obstruction over time (forced expiratory volume in 1 second/forced vital capacity ratio <0.7)\" and \"exposure to noxious particles/gases, with ≥10 pack-years for (ex-)smokers\"; minor criteria were \"lack of response on acute bronchodilator test\"; \"reduced diffusion capacity\"; \"limited variability in airway obstruction\"; \"age >40 years\"; \"emphysema on chest computed tomography scan\". Specific criteria were identified that may guide physicians to a more uniform diagnostic approach for ACOS in COPD or asthma patients. These criteria are largely similar to those used to prescribe inhaled corticosteroids in COPD.

Background To evaluate the outcome of patients treated with stereotactic ablative body radiotherapy (SABR) with curative intent for stage I non-small cell lung cancer (NSCLC) with regard to local, regional and distant tumor control, disease-free survival (DFS), overall survival (OS) and toxicity. Methods Data of 300 patients treated with SABR for NSCLC cancer for the period of November 2007 to June 2016 were retrospectively analyzed. Of which, 189 patients had single primary lung lesion and were included in the study. The prescribed dose for the tumor was 48 Gy, given in 12 Gy × 4 fractions for all patients. In 2010, an improved protocol was established in advanced technology for the planning CT, dose calculation and imaging. Cumulative incidence function (CIF) of local, regional, distant or any recurrences were computed using competing risk analysis with death as a competing event. Survivals (DFS and OS) were estimated using the Kaplan-Meier method and Cox proportional regression was used for comparisons. Toxicities were graded according to the common terminology criteria for adverse events version 4.0 (CTCAE v.4). Results Diagnosis was histologically confirmed in 42% of the patients ( N  = 80). At 1, 2 and 4 years, the cumulative incidence function (CIF) of local relapses were 8% [4–13%], 15% [10–21%] and 18% [12–25%], the CIF of regional relapses were 4% [2–8%], 10% [6–16%] and 12% [8–19%], the CIF of distant relapses were 9% [5–14%], 15% [11–22%] and 20% [15–28%] and the CIF of any relapses were 14% [10–20%], 28% [22–36%], 34% [27–43%], respectively. After 1, 2 and 4 years, the OS rates were 83% [95% CI: 78–89%] ( N  = 128), 65% [95% CI: 57–73%] ( N  = 78) and 37% [95% CI: 29–47%] ( N  = 53), respectively. The median survival time was 37 months. The DFS after 1, 2 and 4 years reached 75% [95% CI: 68–81%] ( N  = 114), 49% [95% CI: 42–58%] ( N  = 60) and 31% [95% CI: 24–41%] ( N  = 41), respectively. No grade 4 or 5 toxicity was observed. Conclusions We observed a long-term local control and survival after SABR for peripheral stage I NSCLC in this large series of patients with the expected low toxicity.

Lung hyperinflation is a main determinant of dyspnoea in patients with chronic obstructive pulmonary disease (COPD). Surgical or bronchoscopic lung volume reduction are the most efficient therapeutic approaches for reducing hyperinflation in selected patients with emphysema. We here report the case of a 69-year old woman with COPD (GOLD stage 3-D) referred for lung volume reduction. She complained of persistent disabling dyspnoea despite appropriate therapy. Chest imaging showed marked emphysema heterogeneity as well as severe hyperinflation of the right lower lobe. She was deemed to be a good candidate for bronchoscopic treatment with one-way endobronchial valves. In the absence of interlobar collateral ventilation, 2 endobronchial valves were placed in the right lower lobe under general anaesthesia. The improvement observed 1 and 3 months after the procedure was such that the patient no longer met the pulmonary function criteria for COPD. The benefit persisted after 3 years.